Opgen Inc

NASDAQ:OPGN   3:59:57 PM EDT
2.31
+0.02 (+0.87%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)47.17M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.4 Million
Adjusted EPS-$0.32
See more estimates
10-Day MA$2.20
50-Day MA$1.99
200-Day MA$2.14
See more pivots

OPGEN INC Stock, NASDAQ:OPGN

708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG, MD 20878
United States of America
Phone: 240-813-1260
Number of Employees: 48

Description

OpGen, Inc. engages in developing and deploying precision medicine tools to combat infectious disease in global healthcare settings. It helps physicians enhance patient outcomes by providing information about life-threatening infections and decreasing the spread of infections caused by multidrug-resistant microorganisms. The company offers a portfolio of in vitro diagnostic products and clinical laboratory services that employ molecular diagnostics and bioinformatics. Its QuickFISH products are a suite of FDA-cleared and CE-marked diagnostics used to detect pathogens in positive blood cultures. The company provides Acuitas MDRO gene test to identify the presence of antibiotic resistant genes for high-risk patients quickly and with high sensitivity and specificity; and Acuitas Lighthouse MDRO management system, which offers epidemiological typing, tracking, and trending to inform infection control, surveillance, and antibiotic stewardship decision makers. In addition, it offers Acuitas whole genome sequence analysis for transmission investigations and epidemiology research. OpGen, Inc. has a strategic collaboration with Hitachi High-Technologies Corporation to commercialize its genome mapping technology for mapping, assembly, and analysis of human DNA. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.